Codexis, Bristol-Myers Squibb Sign Research Agreement
The research with Bristol-Myers Squibb focuses on improving biocatalyst productivity for an undisclosed product candidate in Bristol-Myers Squibb's pipeline using Codexis' proprietary pharmaceutical process re-engineering platform. Codexis will receive research funding and a milestone payment upon successful completion of certain objectives of the research. If Bristol-Myers Squibb is satisfied with the progress of the research, the agreement may subsequently be expanded to fund additional research. Financial terms were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.